The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Pathological gambling in Parkinson disease is reduced by amantadine
Abstract
To investigate the possible efficacy of amantadine in the control of pathological gambling (PG) associated with Parkinson disease (PD), 17 PD patients with PG were randomly selected for a double‐blind crossover study with amantadine 200mg/day versus placebo and an open follow‐up. Assessments included PG‐specific scales (Yale‐Brown Obsessive‐Compulsive Scale for PG, Gambling‐Symptom Assessment Scale, South Oaks Gambling Screen) and assessment of expenditures and time spent gambling. Amantadine abolished or reduced PG in all treated patients, as confirmed by scale score and daily expenditure reduction. Amantadine might be useful to treat PG. The effect of amantadine, acting as an antiglutamatergic agent, also opens new insights into the pathogenesis of PG. ANN NEUROL 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
The glutamate homeostasis hypothesis of addiction
Kalivas, P. W. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2515 · Cited by 1,350
The gambling symptom assessment scale (G-SAS): a reliability and validity study
Kim, S. W., Grant, J. E., Potenza, M. N., Blanco, C., & Hollander, E. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2007.11.008 · Cited by 257
Dopamine dysregulation syndrome in Parkinson's disease
Evans, A. H., & Lees, A. J. (2004) · Current Opinion in Neurology · doi:10.1097/01.wco.0000137528.23126.41 · Cited by 257
Cited by
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
The neuropsychiatry of Parkinson's disease: advances and challenges
Weintraub, D., Aarsland, D., Chaudhuri, K. R., Dobkin, R. D., Leentjens, A. F., Rodriguez-Violante, M., & Schrag, A. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00330-6 · Cited by 450
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update
Voon, V., Napier, T. C., Frank, M. J., Sgambato-Faure, V., Grace, A. A., Rodriguez-Oroz, M., Obeso, J., Bezard, E., & Fernagut, P.-O. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30004-2 · Cited by 359
Metadata
- Authors
- Thomas, A., Bonanni, L., Gambi, F., Di Iorio, A., & Onofrj, M.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-08-30
- Volume
- 68
- Issue
- 3
- Pages
- 400-404
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2146569032
- Cited by
- 235
- References
- 5
- FWCI
- 22.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathological gambling in Parkinson disease is reduced by amantadine. https://app.cochat.ai/papers/10.1002/ana.22029
- The paper
- Thomas, A., Bonanni, L., Gambi, F., Di Iorio, A., & Onofrj, M. (2010). Pathological gambling in Parkinson disease is reduced by amantadine. Annals of Neurology. https://doi.org/10.1002/ana.22029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
